The article by Matsui et al.
1 comes 9 years after our own study dealing with the same topic, that is, the value of CD34 enumeration in bone marrow (BM) to separate hypoplastic myelodysplastic syndrome (h-MDS) and aplastic anemia (AA). 2 The results that the authors report in their study are remarkably similar to ours. Differences in the microwave retrieval process may explain the slightly different percental values obtained by immunohistochemistry. Similar to the authors, we also found a statistically significant difference between the two groups (h-MDS vs AA).
The paper by Matsui et al. 1 is, however, highly inaccurate in the way it quotes our previous study. The authors seem to imply that we did not observe significant differences between the two groups and they stress the 'overlapping' results obtained by several groups and by us (see authors' reference 10). This is totally false. Our results speak for themselves. Our conclusions were the following: 'Bone marrow specimens of h-MDS cases showed statistically higher values of proliferating cell nuclear antigen (PCNA) and CD34 than did those of the AA cases: mean values (7s.d.) of CD34-positive cells in h-MDS, 0.94%71.1; AA, 0.04%70.1 (P ¼ 0.0002); PCNA-positive cells in h-MDS, 43.59%713.3; AA, 14.80%76.4 (Po0.0001)'. Our study confirms that AA is characterized by low expression of PCNA in bone marrow and reduced CD34 frequency compared with h-MDS and supports the concept of an early deficiency of stem cells in the former disorder. The results also illustrate how immunostaining permits a simple distinction of these conditions in routinely processed BM biopsy specimens'. The use of PCNA in this diagnostic context was previously reported by Kitagawa et al. 3 Additionally, the comments in regard to our database, which are found in the discussion section (last page of the discussion, sentence beginning with 'Although Orazi et aly') are also quite inappropriate. Our cases were diagnosed in accordance with the French-American-British guidelines and were not 'misclassified'. Marrow karyotype was normal in only 28% of our cases of MDS. Contrary to what the authors seem to imply, a large proportion of patients with h-MDS do have indeed normal cytogenetics and an indolent clinical course. The separation of AA and h-MDS is problematic only in these cases and not in the group of MDS with an increased number of blasts (i.e. refractory anemia with excess of blasts). The utility of a correct separation between the two conditions lies in the need for a different conditioning regimen when bone marrow transplant is considered, particularly in younger patients with AA, and not necessarily in its prognostic value.
It is truly discouraging to note how some of our younger colleagues are eager to 'reinvent the wheel'.
Reply to 'Quantification of marrow CD34 þ cells: an important tool for distinguishing between hypoplastic myelodysplastic syndromes and aplastic anemia' by A Orazi The intent of our study 1, 2 was not to displace previous reports (including the one authored by Dr Orazi), 3 but rather to provide further evidence that quantification of CD34 þ cells can serve as a useful discriminator between aplastic anemia (AA) and hypoplastic myelodysplastic syndrome (hMDS). Dr Orazi is, in fact, misquoting our paper when he states that we imply that his group did not observe significant differences between the two groups. We acknowledge throughout our paper that the study of Orazi et al.
2 demonstrated a significant difference in the mean percentage of CD34 þ cells from patients classified as having either hMDS or AA. Further, our statement that there is overlap in the range of values given for the hMDS group is quite accurate, with a lower limit (0.1%) in these patients that is equal to the upper value given for those in the AA group. A potential confounding factor in their analysis may have come from reliance on the FAB guidelines to accurately diagnose patients, as those patients with normal cytogenetics and erythroid dysplasia as the sole morphologic abnormality may have in fact have had AA.
Despite the paper published 9 years ago by Dr Orazi and coworkers, enumeration of CD34 in the marrow has not become a Leukemia (2006) 
